Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy

PURPOSE: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in over-active bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg). MATERIALS AND METHODS: We enrolled OAB patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Investig Clin Urol
Autors principals: Shin, Jung Hyun, Kim, Aram, Choo, Myung-Soo
Format: Artigo
Idioma:Inglês
Publicat: The Korean Urological Association 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494350/
https://ncbi.nlm.nih.gov/pubmed/28681036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.2017.58.4.261
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars